<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2016-11-118-122</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-1551</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>РЕВМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>RHEUMATOLOGY</subject></subj-group></article-categories><title-group><article-title>МЕДЛЕННОДЕЙСТВУЮЩИЕ АНТИАРТРОЗНЫЕ ПРЕПАРАТЫ В ЛЕЧЕНИИ ОСТЕОАРТРИТА</article-title><trans-title-group xml:lang="en"><trans-title>SLOW-ACTING ANTI-ARTHROSIS MEDICATIONS FOR THE TREATMENT OF OSTEOARTHRITIS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>СВЕТЛОВА</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>SVETLOVA</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><bio xml:lang="en"><p>MD, Prof.</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Петрозаводский государственный университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Petrozavodsk State University (PetrGU), Petrozavodsk</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2016</year></pub-date><volume>0</volume><issue>11</issue><fpage>118</fpage><lpage>122</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; СВЕТЛОВА М.С., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">СВЕТЛОВА М.С.</copyright-holder><copyright-holder xml:lang="en">SVETLOVA M.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/1551">https://www.med-sovet.pro/jour/article/view/1551</self-uri><abstract><p>В статье рассматриваются эпидемиологические и патогенетические аспекты остеоартрита, а также современные подходы к лечению заболевания, и прежде всего применение медленнодействующих антиартрозных препаратов, хондроитина сульфата, глюкозамина и их комбинации. Представлены результаты исследований последних лет, в которых изучалось влияние вышеназванных препаратов на симптомы, прогрессирование остеоартрита, а также некоторые плейотропные эффекты комбинации хондроитина сульфата и глюкозамина.</p></abstract><trans-abstract xml:lang="en"><p>The article tells about the epidemiological and pathogenetic aspects of osteoarthritis, current treatment approaches, primarily highlighting the slow-acting anti-arthrosis medications, chondroitin sulphate, glucosamine and their combinations. There are results of recent trials which studied the effect of the above mentioned medications on the symptoms and progression of osteoarthritis, as well as several pleiotropic effects of the combination of chondroitin sulfate and glucosamine.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>остеоартрит</kwd><kwd>хондроитин сульфат</kwd><kwd>глюкозамин</kwd><kwd>Терафлекс</kwd></kwd-group><kwd-group xml:lang="en"><kwd>osteoarthritis</kwd><kwd>chondroitin sulfate</kwd><kwd>glucosamine</kwd><kwd>Theraflex</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Балабанова Р.М., Эрдес Ш.Ф. Динамика распространенности ревматических заболеваний, входящих в XIII класс МКБ-10, в популяции взрослого населения Российской Федерации за 2000-2010 гг. Научно-практическая ревматология, 2012 3: 10-12.</mixed-citation><mixed-citation xml:lang="en">Балабанова Р.М., Эрдес Ш.Ф. Динамика распространенности ревматических заболеваний, входящих в XIII класс МКБ-10, в популяции взрослого населения Российской Федерации за 2000-2010 гг. Научно-практическая ревматология, 2012 3: 10-12.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Галушко Е.А., Эрдес Ш.Ф., Алексеева Л.И. Остеоартроз в амбулаторной практике. Современная ревматология, 2012, 4: 66-70.</mixed-citation><mixed-citation xml:lang="en">Галушко Е.А., Эрдес Ш.Ф., Алексеева Л.И. Остеоартроз в амбулаторной практике. Современная ревматология, 2012, 4: 66-70.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Цурко В.В., Хитров Н.А. Остеоартроз: патогенез, клиника, лечение. Лечащий врач, 2000, 9: 23-28.</mixed-citation><mixed-citation xml:lang="en">Цурко В.В., Хитров Н.А. Остеоартроз: патогенез, клиника, лечение. Лечащий врач, 2000, 9: 23-28.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов Е.Л. Современные направления терапии остеоартроза. Consilium Medicum, 2001, 9: 408-415.</mixed-citation><mixed-citation xml:lang="en">Насонов Е.Л. Современные направления терапии остеоартроза. Consilium Medicum, 2001, 9: 408-415.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Митрофанов В.А., Жаденов И.И., Пучиньян Д.М. Остеоартроз: факторы риска, патогенез и современная терапия. Саратовский научно-медицинский журнал, 2008, 2: 23-31.</mixed-citation><mixed-citation xml:lang="en">Митрофанов В.А., Жаденов И.И., Пучиньян Д.М. Остеоартроз: факторы риска, патогенез и современная терапия. Саратовский научно-медицинский журнал, 2008, 2: 23-31.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Чичасова Н.В. Лечение боли у больных остеоартрозом различной локализации. Лечащий врач, 2014, 7: 44-50.</mixed-citation><mixed-citation xml:lang="en">Чичасова Н.В. Лечение боли у больных остеоартрозом различной локализации. Лечащий врач, 2014, 7: 44-50.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Zegels B., Crozes P., Reginster J.Y. Equivalense of single dose (1200 mg) compared to a threetime a day dose (400 mg) of chondroitin sulfate in patients with knee osteoarthritis. Results of a randomized double-blind placebo controlled study. Osteoarthritis and cartilage, 2012, 21: 22-27.</mixed-citation><mixed-citation xml:lang="en">Zegels B., Crozes P., Reginster J.Y. Equivalense of single dose (1200 mg) compared to a threetime a day dose (400 mg) of chondroitin sulfate in patients with knee osteoarthritis. Results of a randomized double-blind placebo controlled study. Osteoarthritis and cartilage, 2012, 21: 22-27.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Martel-Pelletier J, Roubille C, Raynauld J-P. The long-term effects of SYSADOA treatment on knee osteoarthritis symptoms and progression of structural changes: participants from the osteoarthritis initiative progression cohort. Osteoarthritis and cartilage, 2013, 21: 63-312.</mixed-citation><mixed-citation xml:lang="en">Martel-Pelletier J, Roubille C, Raynauld J-P. The long-term effects of SYSADOA treatment on knee osteoarthritis symptoms and progression of structural changes: participants from the osteoarthritis initiative progression cohort. Osteoarthritis and cartilage, 2013, 21: 63-312.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Martel-Pelletier J, Mineau F, Montell E et al. Effect of chondroitin sulfate on the factors involved in synovial inflammation. Osteoarthritis and cartilage, 2012, 54-296.</mixed-citation><mixed-citation xml:lang="en">Martel-Pelletier J, Mineau F, Montell E et al. Effect of chondroitin sulfate on the factors involved in synovial inflammation. Osteoarthritis and cartilage, 2012, 54-296.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wu W, Pasierb M. Physiological concentrations of glucosamine sulfate and glucosamine HCL can downregulate IL-1, kinins and MMPs in human osteoarthritic chondrocytes. Osteoarthritis and cartilage, 2012, 54-296.</mixed-citation><mixed-citation xml:lang="en">Wu W, Pasierb M. Physiological concentrations of glucosamine sulfate and glucosamine HCL can downregulate IL-1, kinins and MMPs in human osteoarthritic chondrocytes. Osteoarthritis and cartilage, 2012, 54-296.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hochberg MC, Martel-Pelletier J, Monfort J et. al. Randomized, double-blind, multicenter, non inferiority clinical trial with combined glucosamine and chondroitin sulfate vs celecoxib for painful knee osteoarthritis. Osteoarthritis and cartilage, 2014, 20: 7-56.</mixed-citation><mixed-citation xml:lang="en">Hochberg MC, Martel-Pelletier J, Monfort J et. al. Randomized, double-blind, multicenter, non inferiority clinical trial with combined glucosamine and chondroitin sulfate vs celecoxib for painful knee osteoarthritis. Osteoarthritis and cartilage, 2014, 20: 7-56.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Fransen М. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis, 2013, 20: 3954. Published Online First 6 January 2014.</mixed-citation><mixed-citation xml:lang="en">Fransen М. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis, 2013, 20: 3954. Published Online First 6 January 2014.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Наумов А.В., Алексеева Л.И., Верткин А.Л. Ведение больных с остеоартритом и коморбидностью в общей врачебной практике. Клинические рекомендации консенсуса экспертов Российской Федерации. Москва, 2015.</mixed-citation><mixed-citation xml:lang="en">Наумов А.В., Алексеева Л.И., Верткин А.Л. Ведение больных с остеоартритом и коморбидностью в общей врачебной практике. Клинические рекомендации консенсуса экспертов Российской Федерации. Москва, 2015.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lambert C. Characterization of synovial angiogenesis in osteoarthritis patients and its modulation by chondroitin sulfate. Arthritis Research &amp; Therapy, 2012, 14: R58.</mixed-citation><mixed-citation xml:lang="en">Lambert C. Characterization of synovial angiogenesis in osteoarthritis patients and its modulation by chondroitin sulfate. Arthritis Research &amp; Therapy, 2012, 14: R58.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Salta JA. Cancer Epidemiol. Biomarkers Prev, 2009, 18: 1419-1428.</mixed-citation><mixed-citation xml:lang="en">Salta JA. Cancer Epidemiol. Biomarkers Prev, 2009, 18: 1419-1428.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Bell GA. Eur Epidemiol, 2012, 27: 593-603.</mixed-citation><mixed-citation xml:lang="en">Bell GA. Eur Epidemiol, 2012, 27: 593-603.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Navarro SL. PloS One, 2015, 26: 45-49.</mixed-citation><mixed-citation xml:lang="en">Navarro SL. PloS One, 2015, 26: 45-49.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Светлова М.С. Остеоартроз коленного сустава: диагностика и структурно-модифицирующая терапия Терафлексом. РМЖ, 2011, 19(19): 1959-1964.</mixed-citation><mixed-citation xml:lang="en">Светлова М.С. Остеоартроз коленного сустава: диагностика и структурно-модифицирующая терапия Терафлексом. РМЖ, 2011, 19(19): 1959-1964.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
